The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Very-large-scale production of antibodies in plants: The biologization of manufacturing
Open accessAbstract
Gene technology has facilitated the biologization of manufacturing, i.e. the use and production of complex biological molecules and systems at an industrial scale. Monoclonal antibodies (mAbs) are currently the major class of biopharmaceutical products, but they are typically used to treat specific diseases which individually have comparably low incidences. The therapeutic potential of mAbs could also be used for more prevalent diseases, but this would require a massive increase in production capacity that could not be met by traditional fermenter systems. Here we outline the potential of plants to be used for the very-large-scale (VLS) production of biopharmaceutical proteins such as mAbs. We discuss the potential market sizes and their corresponding production capacities. We then consider available process technologies and scale-down models and how these can be used to develop VLS processes. Finally, we discuss which adaptations will likely be required for VLS production, lessons learned from existing cell culture-based processes and the food industry, and practical requirements for the implementation of a VLS process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 2×
“…campaign scaled to entire countries or regions would therefore require 50–100 t of mAb per year, far outstripping the capacity of even the largest current processes and defining a new era of very-large-scale (VLS) production more akin to the food processing industry (Lokhorst et al., 2015).”
Background
Cited by
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
In vitro plant tissue culture: means for production of biological active compounds
Espinosa-Leal, C. A., Puente-Garza, C. A., & García-Lara, S. (2018) · Planta · doi:10.1007/s00425-018-2910-1 · Cited by 582
Tripathi, N. K., & Shrivastava, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00420 · Cited by 575
Challenges in the Development of Soft Sensors for Bioprocesses: A Critical Review
Brunner, V., Siegl, M., Geier, D., & Becker, T. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.722202 · Cited by 100
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Metadata
- Authors
- Buyel, J. F., Twyman, R. M., & Fischer, R.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 35
- Issue
- 4
- Pages
- 458-465
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2602116138
- Cited by
- 168
- References
- 1
- FWCI
- 12.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Very-large-scale production of antibodies in plants: The biologization of manufacturing. https://app.cochat.ai/papers/10.1016/j.biotechadv.2017.03.011
- The paper
- Buyel, J. F., Twyman, R. M., & Fischer, R. (2017). Very-large-scale production of antibodies in plants: The biologization of manufacturing. Biotechnology Advances. https://doi.org/10.1016/j.biotechadv.2017.03.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.